UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 222

Sortiert nach

Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial

Lancet neurology, 2014-10, Vol.13 (10), p.977-986

2014

Link zum Volltext

Verfügbarkeit prüfen

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

Lancet neurology, 2009-03, Vol.8 (3), p.254-260

2009

Link zum Volltext

Verfügbarkeit prüfen

A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis

The New England journal of medicine, 2006-03, Vol.354 (9), p.899-910

2006

Link zum Volltext

Verfügbarkeit prüfen

A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis

The New England journal of medicine, 2003-01, Vol.348 (1), p.15-23

2003

Link zum Volltext

Verfügbarkeit prüfen

Assessment of JC virus DNA in blood and urine from natalizumab-treated patients

Annals of neurology, 2010-09, Vol.68 (3), p.304-310

2010

Link zum Volltext

Verfügbarkeit prüfen

Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis

Neurology, 2013-08, Vol.81 (6), p.552

2013

Link zum Volltext

Verfügbarkeit prüfen

Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

Neurology, 2010-05, Vol.74 (18), p.1463

2010

Link zum Volltext

Verfügbarkeit prüfen

Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years

Multiple sclerosis, 2012-09, Vol.18 (9), p.1278-1289

2012

Link zum Volltext

Verfügbarkeit prüfen

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL

Journal of neurology, 2009-03, Vol.256 (3), p.405-415

2009

Link zum Volltext

Verfügbarkeit prüfen

Adherence to Multiple Sclerosis Disease-Modifying Therapies in Ontario is Low

Canadian journal of neurological sciences, 2011-05, Vol.38 (3), p.429-433

2011

Link zum Volltext

Verfügbarkeit prüfen

Severity of chronic pain and its relationship to quality of life in multiple sclerosis

Multiple sclerosis, 2005-06, Vol.11 (3), p.322-327

2005

Link zum Volltext

Verfügbarkeit prüfen

Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis

Multiple sclerosis, 2011-08, Vol.17 (8), p.970-979

2011

Link zum Volltext

Verfügbarkeit prüfen

Health-related quality of life in multiple sclerosis: effects of natalizumab

Annals of neurology, 2007-10, Vol.62 (4), p.335-346

2007

Link zum Volltext

Verfügbarkeit prüfen

Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions

Multiple sclerosis and related disorders, 2016-01, Vol.5, p.97-104

2016

Link zum Volltext

Verfügbarkeit prüfen

Clinical effects of natalizumab on multiple sclerosis appear early in treatment course

Journal of neurology, 2013-05, Vol.260 (5), p.1388-1395

2013

Link zum Volltext

Verfügbarkeit prüfen

Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS

Journal of neurology, 2012-05, Vol.259 (5), p.898-905

2012

Link zum Volltext

Verfügbarkeit prüfen

Multiple sclerosis relapses are associated with increased fatigue and reduced health-related quality of life – A post hoc analysis of the TEMSO and TOWER studies

Multiple sclerosis and related disorders, 2016-05, Vol.7, p.33-40

2016

Link zum Volltext

Verfügbarkeit prüfen

Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study

Journal of neurology, 2014-09, Vol.261 (9), p.1781-1788

2014

Link zum Volltext

Verfügbarkeit prüfen

Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use

Journal of neurology, 2013-10, Vol.260 (10), p.2472-2480

2013

Link zum Volltext

Verfügbarkeit prüfen

4-aminopyridine toxicity with unintentional overdose in four patients with multiple sclerosis

Neurology, 2008-11, Vol.71 (22), p.1833

2008

Link zum Volltext

Verfügbarkeit prüfen

The Toronto Observational Study of Natalizumab in Multiple Sclerosis

Canadian journal of neurological sciences, 2011-05, Vol.38 (3), p.422-428

2011

Link zum Volltext

Verfügbarkeit prüfen

Multiple Sclerosis Disease-Modifying Therapy Prescribing Patterns in Ontario

Canadian journal of neurological sciences, 2013-01, Vol.40 (1), p.67-72

2013

Link zum Volltext

Verfügbarkeit prüfen

Increasing use of disease modifying drugs for MS in Canada

Canadian journal of neurological sciences, 2010-05, Vol.37 (3), p.383

2010

Link zum Volltext

Verfügbarkeit prüfen

Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes: a 10-year follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance

Archives of neurology (Chicago), 2012-02, Vol.69 (2), p.183

2012

Link zum Volltext

Verfügbarkeit prüfen

Sensitivity of repetitive facial-nerve stimulation in patients with myasthenia gravis

Muscle & nerve, 2006-05, Vol.33 (5), p.694-696

2006

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 222

Suche als RSS-Feed

Aktive Filter

ThemaFemale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(204)
Mit Volltextzugriff
(194)

Publikationsform

Artikel
(222)

Sprache

Englisch
(222)
Japanisch
(35)
Spanisch
(1)

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis

A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis

Assessment of JC virus DNA in blood and urine from natalizumab-treated patients

Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis

Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL

Adherence to Multiple Sclerosis Disease-Modifying Therapies in Ontario is Low

Severity of chronic pain and its relationship to quality of life in multiple sclerosis

Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis

Health-related quality of life in multiple sclerosis: effects of natalizumab

Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions

Clinical effects of natalizumab on multiple sclerosis appear early in treatment course

Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS

Multiple sclerosis relapses are associated with increased fatigue and reduced health-related quality of life – A post hoc analysis of the TEMSO and TOWER studies

Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study

Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use

4-aminopyridine toxicity with unintentional overdose in four patients with multiple sclerosis

The Toronto Observational Study of Natalizumab in Multiple Sclerosis

Multiple Sclerosis Disease-Modifying Therapy Prescribing Patterns in Ontario

Increasing use of disease modifying drugs for MS in Canada

Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes: a 10-year follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance

Sensitivity of repetitive facial-nerve stimulation in patients with myasthenia gravis

Aktive Filter

Suchergebnisse filtern